RxDoctor Payments Data

Ronald Sherman, DPM

Foot Surgery · Baltimore, MDNPI 1780773226

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (34.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Kerecis Limited at 39.2% of the total.

$7,318in general payments, 2019–2025

Across 32 payments — averaging $228.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kerecis Limited$3K
  • Integra Lifesciences Corporation$2K
  • Mimedx Group, Inc.$1K
  • Smith+Nephew$529
  • Stryker$450
  • Medline Industries LP$123
  • plus $74 from 2 others

What the payments were for

  • Consulting fees$1,51321%
  • Speaking & faculty fees$5638%
  • Grants$2,50034%
  • Travel & lodging$1,38219%
  • Food & beverage$1,34318%
  • Education$180%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Kerecis Limited5$2,871
Integra Lifesciences Corporation7$2,070
Mimedx Group, Inc.7$1,202
Smith+Nephew8$529
Stryker2$450
Medline Industries LP1$123
Orpyx Medical Technologies US Inc.1$56
KCI USA, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,318 in reported general payments places this provider in the 85th percentile of 28 foot surgery providers in Maryland.

See all foot surgery providers in Maryland

Medicare billing

Part B allowed, 2024
$94,114
Medicare patients
178
Services billed
666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Doxycycline Hyclate11$103

Paid to pharmacies, not to this prescriber.

Other foot surgery in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →